1Shanes JG, Minadeo KN, Moret A, et al . Statin therapy in heart failure: Prognostic effects and potential mechanisms[J]. Am Heart J ,2007,154:617-623.
2Anker SD, yon Haehling S, Inflammatory mediators in chronic heart failure:an overview[J]. Heart , 2004,90:464-470.
3Liao JK. Isoprenoids as mediators of the biological effects of statins[J]. J Clin Invest ,2002,110:285-288.
4Repko EM, Maltese WA. Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability[J]. J Biol Chem ,1989,264:9945-9952.
5Ridker PM. Connecting the role of C-reactive protein and st atins in cardiovascular disease[J]. CAin Cardiol , 2003, 26 (Suppl 3) : III-39-III-44.
6Fonarow GC, Wright RS, Spencer FA, et al . For the National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality[J]. Am J Cardiol ,2005,96:611-616.
7Schafer A, Fraccarollo D, Eigenthaler M, et al . Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability[J]. Arterioscler Thrornb Vasc Biol , 2005, 25: 1071-1077.
8Hayashidani S. Fluvastatin, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J]. Circulation , 2002,105:868-873.
9Burnier M. Angiotensin Ⅱ type Ⅰ receptor blockers[J]. Circulation , 2001. 103 : 904-912.
10Krum H. UNIVERSE: rosuvastatin has no effect on ventricular remodeling[S]. Presented at the annual meeting of the American College of Cardiology , Atlanta, Georgia,2006.
